Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
AKBA
AKBA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AKBA News
Akebia (AKBA) Q4 2025 Earnings Call Transcript
Feb 26 2026
NASDAQ.COM
Akebia Expects Significant Revenue Growth for Vafseo in 2026
Feb 26 2026
stocktwits
Akebia Therapeutics Q4 2025 Earnings Call Insights
Feb 26 2026
seekingalpha
Akebia Reports Q4 Earnings Beat with Revenue Growth
Feb 26 2026
seekingalpha
Akebia Scheduled to Announce Q4 Earnings on February 26
Feb 25 2026
seekingalpha
Akebia Doses First Patient in Phase 2 Trial of Praliciguat for FSGS
Jan 07 2026
NASDAQ.COM
Akebia Doses First Patient in Phase 2 Trial of Praliciguat for FSGS
Jan 06 2026
Globenewswire
Akebia Grants 197,900 Stock Options to New Employee
Jan 05 2026
Globenewswire
What’s Driving the Surge in Small-Cap Q32 Bio Stock This Monday?
Dec 01 2025
Benzinga
Q32 Bio Sells ADX-097 for $12M, Extends Cash Runway into 2027
Dec 01 2025
PRnewswire
Akebia Acquires Q32 Bio's Next-Gen Kidney Disease Treatment
Dec 01 2025
Newsfilter
Akebia Reports GAAP EPS of $0.00, Exceeding Estimates by $0.01; Revenue of $58.78M Surpasses Expectations by $2.36M
Nov 10 2025
SeekingAlpha
Mettler-Toledo Exceeds Q3 Earnings Expectations Despite Year-over-Year Sales Drop
Nov 07 2025
NASDAQ.COM
Three Health Care Stocks That Could Revitalize Your Portfolio This November
Nov 04 2025
Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Akebia Therapeutics, Adjusts Price Target to $6
Oct 30 2025
Benzinga
FDA Resistance Leads Akebia to Abandon Efforts for Expansive Label on Kidney Disease Medication
Oct 29 2025
Benzinga
Show More News
